N/A
N=15
Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
Malignant Solid Neoplasm
Bottom Line
View on ClinicalTrials.gov: NCT04870645 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Advanced Magnetic Resonance Imaging (Procedure); Conventional Magnetic Resonance Imaging (Procedure); Gadolinium-Chelate (Drug); Iopamidol (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- M.D. Anderson Cancer Center
- Primary completion
- Aug 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Contrast to Noise Ratio |
3.2 | < 0.05 sig |
Summary
This clinical trial studies the different types of investigational imaging techniques called sequences during magnetic resonance imaging (MRI) of the head before and after radiation therapy in patients with cancer that has spread to the brain (intracranial metastases). This clinical trial also compares these new techniques with standard MRI imaging to see if sequences provide better images. Diagnostic procedures, such as MRI, may help find and diagnose solid organ cancer and find out how far the disease has spread.
Eligibility Criteria
Inclusion Criteria
- An adult patient with pathology-proven solid organ cancer
- MRI of the brain with contrast, positive for at least one intra-axial metastatic lesion greater than 5 mm
- Planned treatment with stereotactic radiation
Exclusion Criteria
- Contraindication to MR imaging
- Known allergy to gadolinium-based contrast agents
- Renal failure as defined by a glomerular filtration rate (GFR) less than 30 or the use of hemodialysis
- Pregnant
- Patients less than 18 years of age will be excluded
Data sourced from ClinicalTrials.gov (NCT04870645). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.